{"entity":{"id":"remedy-plan-therapeutics","kind":"company","name":"Remedy Plan Therapeutics","aka":["Remedy Plan, Inc."],"tldr":"Remedy Plan Therapeutics develops RPT1G, a medicine that blocks NAMPT, an enzyme cancer cells rely on for energy. It is in an early trial in acute myeloid leukaemia and high-risk myelodysplastic syndromes.","summary":"Remedy Plan Therapeutics is a clinical-stage biotechnology company whose lead, RPT1G, is described as a first-in-class hyperbolic inhibitor of NAMPT, an enzyme the company says is dysregulated in many diseases including cancer. After a phase 1 study in healthy adults (NCT06667765) and FDA IND clearance announced in November 2025, RPT1G entered a multi-centre, open-label 3+3 dose-escalation trial in relapsed or refractory acute myeloid leukaemia and high-risk myelodysplastic syndromes (NCT07107126); in September 2026 the company reported that cohort 1 had completed a full 28-day cycle and cohort 2 had begun enrolling. The same release, datelined Gaithersburg, Maryland, reported a Series A extension of about USD 30 million with participation from Schooner Capital and mainly existing investors. Its first registered cancer trial, NCT07107126, was posted on ClinicalTrials.gov in August 2025; its first registry study, the healthy volunteer trial NCT06667765, was posted in October 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.remedyplan.com/"},{"label":"September 2026 milestones and financing release","url":"https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-announces-multiple-development-and-corporate-milestones-as-first-in-class-hyperbolic-nampt-inhibitor-rpt1g-advances-in-phase-1-dose-escalation-trial-in-amlmds"},{"label":"ClinicalTrials.gov: phase 1 trial of RPT1G in AML and MDS (NCT07107126)","url":"https://clinicaltrials.gov/study/NCT07107126"},{"label":"ClinicalTrials.gov: phase 1 healthy volunteer study of RPT1G (NCT06667765)","url":"https://clinicaltrials.gov/study/NCT06667765"}],"tags":[],"related":[],"cancers":["aml","mds-higher-risk"],"sections":["targeted-therapy"],"technologies":["metabolic-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the pages read; headquarters taken from the Gaithersburg, MD dateline.","The technology id metabolic-therapy is used because NAMPT inhibition depletes the NAD supply of cancer cells.","Company website and September 2026 release read on 29 October 2026."],"hq":"Gaithersburg, MD","country":"US","companyType":"biotech","website":"https://www.remedyplan.com/","stage":"startup","investors":[],"funding":[{"round":"Series A extension","year":2026,"amountUsd":30000000,"source":"https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-announces-multiple-development-and-corporate-milestones-as-first-in-class-hyperbolic-nampt-inhibitor-rpt1g-advances-in-phase-1-dose-escalation-trial-in-amlmds","note":"Described as approximately USD 30 million, with Schooner Capital and primarily existing investors."}]},"route":"/companies/remedy-plan-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/"}]}}